Document:

Exhibit 10.4

 

AMENDMENT NUMBER TWO TO AGREEMENT

 

This is the second amendment (“Amendment No. 2”)
to the AMENDED AND RESTATED PATENT LICENSE AGREEMENT (the “License Agreement”), between The Board of
Regents of The University of Texas System (“Board”) on behalf of The University of Texas Health Science Center
at Houston (“UTHSC-H”) and PLx Pharma Inc., a Texas corporation with its principal place of business at 8285
El Rio, Suite 130, Houston, Texas 77054 (“PLx”), with an Effective Date of December 11, 2009. Board,
UTHSC-H, and PLx may individually be referred to as Party or collectively as the Parties. All capitalized or bolded
terms used in this Amendment No. 2 and not otherwise defined herein shall have the meanings assigned to those terms in the
License Agreement.

 

WHEREAS, the parties entered into a the License Agreement,
which such License Agreement was amended by the Amendment Number One To Agreement dated April 15, 2011; and,

 

The parties hereby desire to further amend the License Agreement;

 

Now, therefore, the parties do hereby agree as follows:

 

Section 4.6 shall be amended and restated in its entirety as
follows:

 

		4.6	Reasonable commercial diligence shall require that PLx:

		a.	On or before [*], submit an NDA for a Licensed
Product; and;

		b.	On or before [*], Sell or offer for Sale
a Licensed Product.

 

Except as expressly provided in this Amendment No. 2,
all other terms, conditions and provisions of the License Agreement shall continue in full force and effect as provided
therein.

 

(Signature Page Follows)

 

Amendment No. 2 to Patent License Agreement

The University of Texas System and PLx Pharma, Inc.

 

    	 	Page 1 of 2	 

     

    

  

	On Behalf of the Board of Regents of The University
    of Texas System	 	PLX PHARMA INC.
	 	 	 	 
	By:	/s/ T. Kevin
    Dillon	 	By: 	/s/ Ronald
    R. Zimmerman
	T. Kevin Dillon	 	Ronald R. Zimmerman
	Senior Executive  Vice President, Chief
    Operating and Financial  Officer	 	President and Chief Executive Officer
	University of Texas Health Science Center at Houston	 	 
	 	 	 	 	 
	Date:	12/9/11	 	Date: 	12/17/11

 

	Read and Understood:	 	 
	 	 	 
	By:	/s/ Lenard M. Lichtenberger	 	 
	Lenard M. Lichtenberger Ph.D.	 	 
	Inventor	 	 
	 	 	 
	Date: 	11/30/11	 	 

 

Amendment No. 2 to Patent License Agreement

The University of Texas System and PLx Pharma, Inc.

 

    	 	Page 2 of 2Exhibit 10.5

 

AMENDED
AND RESTATED

LICENSE
& COMMERCIALIZATION AGREEMENT

 

by and between

 

LEE’S
PHARMACEUTICAL holdings Limited, 

 

Zhaoke
Pharmaceutical (HEFEI) Co. Ltd., 

lee’s
pharmaceutical ( guangZhou ) limited 

 

AND

 

PLX
PHARMA llc

 

    	 	1	 

     

    

 

TABLE OF CONTENTS

 

	1. EFFECTIVE DATE	3
	2. DEFINITIONS	3
	3. WARRANTY; SUPERIOR-RIGHTS; SUPPORT	6
	4. LICENSE; CERTAIN LICENSEE OBLIGATIONS	7
	5. PAYMENTS AND REPORTS	11
	6. TERM AND TERMINATION	14
	7. INFRINGEMENT	16
	8. ASSIGNMENT; CHANGE IN CONTROL	16
	9. PATENT MARKING AND MAINTENANCE	17
	10. INDEMNIFICATION	17
	11. USE OF NAME	17
	12. CONFIDENTIAL INFORMATION AND PUBLICATION	17
	13. PATENTS AND INVENTIONS	18
	14. GOVERNING LAW; JURISDICTION; VENUE	19
	15. GENERAL	19

 

    	 	2	 

     

    

 

AMENDED AND RESTATED LICENSE & COMMERCIALIZATION
AGREEMENT

 

This Amended and Restated
License & Commercialization Agreement (“Agreement”) is entered into by and between PLx
Pharma LLC, a Texas limited liability company having a principal place of business located at 8285 El Rio, Suite 130, Houston,
Texas 77054 (“PLx”) and LEE’S PHARMACEUTICAL Holdings Limited
(“Lee’s”), Zhaoke Pharmaceutical (HEFEI) Co. Ltd. (“Zhaoke”),
and LEE’S PHARMACEUTICAL (GUANGzHOU ) LIMITED  (“Guangzhou” ) (Guangzhou and, collectively,
together with Lee’s and Zhaoke, “Licensee”). PLx and Licensee (and, respectively,
Lee’s, Zhaoke and Guangzhou) may individually be referred to as Party or collectively as Parties.

 

RECITALS

 

A.           PLx
owns or is the exclusive licensee of certain Patent Rights and PLx Technology Rights related to Licensed
Subject Matter mainly deriving from an Amended and Restated Patent License Agreement between PLx and the Board of Regents
of the University of Texas System (“System”) dated December 11, 2009, as subsequently amended.

 

B.           Licensee
desires to obtain a license from PLx to develop, register, manufacture, produce and Commercialize the Licensed
Subject Matter in the Licensed Territory.

 

C.           Licensee
and PLx entered into a license agreement dated March 12, 2012, which was subsequently amended by a First Amendment to License Agreement
dated December 21, 2013 (collectively the “Original Agreement”).

 

D.           Effective
December 31, 2013, PLx converted from a corporation to a limited liability company, changing its name from “PLx Pharma
Inc.” to “PLx Pharma LLC.”

 

E.           The
Parties desire to amend and restate the Original Agreement as set forth below.

 

NOW, THEREFORE, in consideration
of the mutual covenants and premises herein contained, the parties agree as follows:

 

1.
EFFECTIVE DATE

 

This Agreement is effective as of
June 19, 2015 (the “Effective Date”).

 

2.
DEFINITIONS

 

As used in this Agreement, the following
terms have the meanings indicated:

 

    	 	3	 

     

    

 

2.1       “Affiliate”
means:

 

(a)          any
business entity at least 50% owned directly or indirectly by Licensee, or

 

(b)          any
business entity that owns directly or indirectly at least 50% of Licensee; or

 

(c)          any
business entity whose operations Licensee has the contractual right or voting power to control; or

 

(d)          any
officer, director, employee, contract worker, and agent of Licensee.

 

2.2        “Actively
Attempting to Commercialize” means a documented, effective, ongoing and active pursuit of approval from all Applicable
Regulatory Authorities for the development, manufacturing, marketing and Sales of Licensed Product(s) within
the Licensed Territory.

 

2.3        “Applicable
Regulatory Authority” means the State Food and Drug Administration (“SFDA”) of the People’s
Republic of China or any other Regulatory Authority with jurisdiction and authority within the Licensed Territory
over approval and regulation of a given Licensed Product.

 

2.4        “cGMP
Product” means a Licensed Product compliant with current Good Manufacturing Practices established by the Applicable
Regulatory Authority.

 

2.5        “Change
in Control” means (i) any sale of all or substantially all of a given entity’s assets, or (ii) any merger, consolidation,
combination, reorganization, or recapitalization, as the result of which the holders of a majority of the voting control of such
entity or the power in fact to control the management decision of such entity immediately before such transaction cease to retain
majority voting control or cease to have the power to control the management decision as the result of such transaction.

 

2.6        “Clinical
Trial Data” means all data, protocols, design, results, and other information related to, prepared for, derived from,
or generated by any clinical trials or other testing conducted by Licensee (or any Sublicensee or contractor thereof)
with respect to a Licensed Product.

 

2.7        “Commercialize”
means having Sales of Licensed Product(s) to an independent entity in a bona fide commercial transaction.

 

2.8        “Combination
Product” means any use of aspirin in combination with other drugs in products using the Licensed Subject Matter.

 

2.9        “Competing
Product” means any gastrointestinal-safer formulation of any aspirin or aspirin derivative formulation.

 

2.10      “Distributor”
means any third party appointed by Licensee or its Affiliates to distribute, market and sell Licensed Products
purchased from Licensee or any of its Affiliates (regardless of whether such third party has the right or obligation
to provide packaging or labeling services with respect to such Licensed Products), provided that such third party does not
have the right to manufacture or produce any Licensed Products without the consent of PLx and does not otherwise
own or license any intellectual property rights in the Licensed Products.

 

    	 	4	 

     

    

 

2.11       “FDA”
means the Food and Drug Administration of the United States of America.

 

2.12       “IND”
means an application submitted to the Applicable Regulatory Authority for a Licensed Product that is reasonably
equivalent to an Investigational New Drug application or a Treatment Investigational New Drug application submitted to the FDA
under 21 C.F.R. Part 312.

 

2.13       2.13
“Licensed Field” means a composition comprising aspirin and one or more of the following: phospholipids, triglycerides,
fatty acids, or glycolipids. For the sake of clarity, “Licensed Field” includes only those products that use
solely aspirin with the Licensed Subject Matter, and excludes Combination Products. Licensee will need to
obtain PLx approval for the marketing or development of any Combination Product, which approval will not be unreasonably
withheld or delayed by PLx.

 

2.14       “Licensed
Product(s)” means any product comprising, containing, incorporating, derived from, or combined with the Licensed
Subject Matter.

 

2.15       “Licensed
Property” means the Licensed Subject Matter and all Inventions.

 

2.16       “Licensed
Subject Matter” means (i) inventions and discoveries covered by Patent Rights or PLx Technology Rights
within Licensed Field, including the PLxGuardTM technology and (ii) all trademark rights held
by PLx in the PLxGuardTM mark.

 

2.17       “Licensed
Territory” means the People’s Republic of China, including Hong Kong and Macao Special Administrative Regions.

 

2.18       “NDA”
means an application submitted to the Applicable Regulatory Authority for a Licensed Product that is reasonably
equivalent to a New Drug Application or an Abbreviated New Drug Application submitted to the FDA under 21 C.F.R. Part 314.

 

2.19       “Net
Sales” shall mean the gross proceeds of Sales
made by Licensee or its Affiliates or its Sublicensees of Licensed Products in the Territory to a third
party, less (i) quantity and/or cash discounts actually allowed or taken to the extent customary, (ii) customs duties, excise taxes,
if any, directly related to the Sale of Licensed Products and actually paid, (iii) amounts allowed by reason of rejections
and return of goods, (iv) third-party rebates related to the Sale of Licensed Products, to the extent allowed and
actually paid, and (v) import tax, value-added tax, and other similar sales taxes related to the sale of Licensed Products
to the extent customary and actually paid. The foregoing notwithstanding, in the calculation of Net Sales no deductions
or exclusions shall be made for any management fees or similar payments made to Licensee, or for any withholding amounts
for tax purposes or any other payments made solely for the benefit of Licensee.

 

2.20       “Optional
Licensed Territory” means Cambodia, Indonesia, Laos, Malaysia, Myanmar, Papua New Guinea, Philippines, Singapore, Taiwan,
Thailand, and Vietnam.

 

2.21       “Patent
License Agreement” means that certain Amended and Restated Patent License Agreement between PLx and System dated December
11, 2009, as subsequently amended.

 

    	 	5	 

     

    

 

2.22       “Patent
Rights” means PLx’s rights in inventions or discoveries covered by patent(s) or patent applications listed
in Attachment A, and any patent(s) issuing from the applications, all divisionals, continuations, reissues, revival, reexaminations
or extensions thereof.

 

2.23       “PLx
Technology Rights” means PLx’s rights in technical information, know-how, trade secrets, processes, procedures,
compositions, devices, methods, formulas, protocols, techniques, software, designs, drawings, databases, or other data related
to the Licensed Product that are not covered by Patent Rights, but which are necessary for using the Licensed Subject
Matter in a manner consistent with the intent of this Agreement.

 

2.24       “Regulatory
Authority” means the Food and Drug Administration of the United States of America (“FDA”) or any comparable
agency in a country outside the United States of America that is authorized to regulate the licensure, approval, manufacture, and
sale of pharmaceuticals, biologics, dietary supplements, medical foods, Nutraceuticals, food additives, cosmetics, diagnostics,
medical devices, and medical processes.

 

2.25       “Royalty”
and “Royalties” means amounts due PLx under Section 5.2.

 

2.26       “Sales,”
“Sale,” “Sold” or “Sell” means the transfer or disposition
of a Licensed Product(s) for consideration to a party other than Licensee or its Affiliates .

 

2.27       “Sublicensee”
means any third party to which Licensee has sub-licensed its rights on the Licensed Products, including the manufacturing
rights under this Agreement. For the sake of clarity and for the purpose of this Agreement, a Distributor
will not be considered a Sublicensee.

 

2.28       “System”
means the University of Texas System and its affiliates.

 

2.29       “Valid
Claim” means, on a country-by-country basis, a granted claim within the Patent Rights which has not been held invalid
and/or unenforceable in a decision of a patent office, court or other government agency of competent jurisdiction, unappealable
or unappealed within the time frame allowed for appeal.

 

It is agreed that the definitions above
shall have the same meaning regardless of whether a term is used in the singular or plural form.

 

3.
WARRANTY; SUPERIOR-RIGHTS; SUPPORT

 

3.1        Except
for the rights of the Government of the United States, as set forth below, PLx represents and warrants its belief that (i)
it is the exclusive licensee of the right, title, and interest in and to Licensed Subject Matter, (ii) it has the right
to grant licenses hereunder, and (iii) it has not knowingly granted licenses to any other entity that would restrict rights granted
to Licensee except as stated herein.

 

3.2        Licensee
understands the Licensed Subject Matter has been developed under a funding agreement with the Government of the United States
of America (“Government”), which may have certain rights relative thereto. This Agreement is explicitly
made subject to the Government’s rights under any agreement and any applicable law or regulation. If there is a conflict
between an agreement, applicable law or regulation and this Agreement, the terms of the Government agreement, applicable
law or regulation shall prevail.

 

    	 	6	 

     

    

 

3.3        Licensee
understands and agrees that PLx, by this Agreement, makes no representation as to the operability or fitness for
any use, safety, efficacy, ability to obtain regulatory approval, patentability, time and cost of development, and/or breadth of
the Licensed Subject Matter.

 

3.4        To
the knowledge of PLx, the inventions contained in the Patent Rights do not infringe any other patents now held or
that will be held by others or by PLx.

 

3.5        Licensee,
by execution hereof, acknowledges, covenants and agrees that it has not been induced in any way by PLx or its employees
to enter into this Agreement, and further warrants and represents that (i) it has conducted sufficient due diligence with
respect to all items and issues pertaining to this Section 3 and all other matters pertaining to this Agreement; and (ii)
Licensee has adequate knowledge and expertise, or has utilized knowledgeable and expert consultants, to adequately conduct
the due diligence, and agrees to accept all risks inherent herein.

 

3.6        Licensee
hereby represents that it does not—and will not during the term of this Agreement—develop, manufacture, or distribute
any Competing Product.

 

3.7        Licensee
and PLx agree that, during the term of this Agreement, PLx shall make its personnel reasonably available—
including within the Licensed Territory —at a rate of [*] per person per day, plus all out-of-pocket expenses—for consultation
with respect to the Licensed Subject Matter and any Licensed Product.

 

3.8        Licensee
agrees (i) that each of Lee’s, Zhaoke, and Guangzhou is jointly and severally liable for the obligations of Licensee
hereunder and (ii) that, in particular, Lee’s’ executing this Agreement as a party hereto was a material inducement
to PLx’s entrance into this Agreement and acceptance of the terms hereof.

 

4.
LICENSE; CERTAIN LICENSEE OBLIGATIONS

 

4.1        PLx
hereby grants to Licensee an exclusive, royalty-bearing license under Licensed Subject Matter to develop, register,
manufacture, have manufactured, use, distribute, have distributed, Sell, offer to Sell, import, lease, loan or otherwise
Commercialize Licensed Product(s) in Licensee’s ordinary course of business within the Licensed Territory.
This grant is subject to any rights held by the Government as set forth in Section 3.2, the payment by Licensee to PLx
of all consideration as provided herein, and is further subject to the following rights retained by PLx and its academic
collaborators (including System) to:

 

(a)          Publish
the scientific findings from research related to Licensed Subject Matter subject to the terms of Section 12, Confidential
Information and Publication; and

 

(b)          Use
Licensed Subject Matter for research, teaching and other educationally-related purposes.

 

    	 	7	 

     

    

 

4.2        Licensee
may extend the license granted herein to any Affiliate, which Affiliate will be bound by this Agreement
to the same extent as Licensee.

 

4.3        Licensee
may grant distribution rights to Distributors. Licensee may only grant sublicensing rights consistent with this
Agreement, and (except in the case of Licensee’s Affiliates) only with the prior written approval of PLx,
which approval will not be unreasonably withheld or delayed. Licensee is responsible for the obligations of Sublicensee(s)
under any sublicense relevant to this Agreement, including the payment of royalties or other consideration whether or
not paid to Licensee by a Sublicensee. Licensee shall require and provide to PLx quarterly reports
consistent with Section 5 herein for each Sublicensee. Licensee shall deliver to PLx a true and correct copy
of each sublicense granted by Licensee to a Sublicensee, and any amendment, modification or termination thereof, within
thirty (30) days after execution, modification, or termination. If this Agreement is terminated, Licensee’s
interest in all existing sublicenses with any Sublicensees shall be regulated according to the provisions set forth in Section
6.4.

 

4.4        Licensee
shall at all times use its best efforts to commercially develop, manufacture or have others manufacture, seek and obtain any necessary
governmental approval, and actively promote, Sell and distribute Licensed Product(s) in the Licensed Territory,
meeting, at a minimum, the following timeline (the requirements set forth in each of subsections 4.4(a) through (h) below are referred
to herein as “Milestones”):

 

(a)          Licensee
confirms that the IND for PL2200 100 mg aspirin will be submitted to the Applicable Regulatory Authority by [*]..

 

(b)          Within
[*] months of Applicable Regulatory Authority approval of an IND, Licensee will commence subject dosing of
a Phase I bioequivalence and pharmacodynamic study using a [*]aspirin dose and a minimum of [*] healthy subjects (the “Phase
I Study”), the clinical endpoint of which is to assess [*]. Licensee will make all efforts to successfully complete the
study within [*] of commencement.

 

(c)          Licensee
will submit the Phase I Study results to the Applicable Regulatory Authority within [*] after completion of the
Phase I Study.

 

(d)          Licensee
will complete an operational production line (for the Licensed Product that is the subject of the Phase I Study)
compliant with applicable regulations of the Applicable Regulatory Authority no later than [*].

 

(e)          Within
[*] months after the successful completion of the Phase I Study and subject to the required approval by the Applicable Regulatory
Authority, Licensee will commence subject dosing of a human clinical endoscopy trial (the “Phase III Study”):

 

(i)          using
100 mg dose PL2200 aspirin;

 

(ii)         including
a minimum of [*];

 

(iii)        including
the performance of endoscopy at [*],[*], and [*];

 

    	 	8	 

     

    

 

(iv)        with
clinical end points that are in line with the following: (A) a reduction in the risk of upper gastrointestinal ulcers (3mm or greater
diameter) using [*] and (B) a lower gastrointestinal endpoint using [*]; and

 

(v)         Licensee
will make all efforts to successfully complete the study within [*] of commencement.

 

(f)          Submission
of an NDA within [*] months of the successful completion of the Phase III Study.

 

(g)          Licensee
will provide PLx a commercial plan within [*] after the successful completion of the Phase III study provided for in Section
4.4 (e). The commercialization plan should be reasonable in scope and detail and reflect the information typically included in
the industry for similar internal commercialization plans, such as market research to develop the product positioning, key messages
and testing of key promotional materials such as visual aids and other brochures targeted to physicians and other healthcare professionals
and patients, and key opinion leader communications and meetings, budget for the first year and forecasts for the second and third
years of such plan, revenue and sales forecasts for three years, pricing strategies, production and supply chain strategies, branding
strategies, labeling, advertising and public relations strategies.  Annual reports subsequent to a product launch shall also
include market trends, market penetration, physician behavior, brand overview, detail summary by sales forces and sales by largest
customers.

 

(h)          Licensee
will commence commercial sales within [*] months of the final NDA approval by the Applicable Regulatory Authority.

 

All
costs associated with the above items shall be the responsibility of Licensee, but Licensee may not initiate any
clinical trial without the prior written consent of PLx, which consent will not be unreasonably withheld or delayed. Upon
a failure of Licensee to satisfy any Milestone set forth in this Section 4.4, Licensee shall have [*] from
the date on which such Milestone was to be completed in which to submit to PLx a revised plan for achieving the
requirements under such Milestone (a “Revised Milestone Plan”), at which point PLx shall have,
in its reasonable opinion, the option to either (i) terminate this Agreement at any time following the end of such [*]
period or (ii) accept such Revised Milestone Plan, and, if deemed appropriate and necessary by the parties, cooperate with
Licensee to effect such amendments to this Agreement as are necessary to revise the applicable Milestone
in accordance with the Revised Milestone Plan.

 

4.5        In
the event that Licensee determines that it requires a license from PLx for other intellectual property owned or
controlled by PLx in the Licensed Field (“Other IP”) in order for Licensee to perform
under this Agreement, PLx agrees to license such Other IP, to the extent so required, to Licensee.

 

    	 	9	 

     

    

 

4.6        Licensee
hereby covenants and agrees that it shall not (and shall cause its Affiliates not to), either directly or indirectly,
market or sell Licensed Products into countries outside of the Licensed Territory. Without limiting the generality
of the foregoing, with respect to such countries outside of the Licensed Territory, Licensee shall not (i) engage
in any promotional activities relating to Licensed Products directed primarily to customers located in such countries,
or (ii) solicit orders from any prospective purchaser located in such countries. Licensee will use best efforts to prevent
third parties from purchasing Licensed Products from Licensee and reselling it outside the Licensed Territory
(“Parallel Exportation”) and, if Licensee becomes aware that any third party is engaging in Parallel
Exportation, Licensee shall (i) promptly inform PLx of same in writing and (ii) use best efforts to induce
such third party to immediately cease such Parallel Exportation.

 

4.7        Licensee
hereby covenants and agrees that it shall not (and shall cause its Affiliates not to), either directly or indirectly, market, distribute
or sell Licensed Products for use outside of the Licensed Field. Without limiting the generality of the foregoing,
Licensee shall not (i) engage in any promotional activities relating to Licensed Products directed at use outside
of the Licensed Field, or (ii) solicit orders from any prospective purchaser for use of Licensed Products outside
of the Licensed Field.

 

4.8        At
least [*] days prior to the initial Sale of any Licensed Product in the Licensed Territory and on at least
an annual basis thereafter, Licensee shall:

 

(a)          Provide
PLx with samples of any Licensed Product to be Sold in the Licensed Territory; and

 

(b)          Provide
PLx the opportunity and access necessary to audit and inspect Licensee’s facilities and operations in order
to verify Licensee’s compliance with all regulations imposed by any Applicable Regulatory Authority.

 

4.9        If
it is reasonably determined by PLx that Licensee’s development or production of a Licensed Product is
not in full compliance with the regulations imposed by any Applicable Regulatory Authority, Licensee shall, immediately
upon delivery of written notice from PLx of such non-compliance, cease all development, production, and distribution operations
until such non-compliance has been remedied. Nothing in this Section 4.9 shall be construed so as to limit PLx’s ability
to terminate this Agreement pursuant to Section 6.3(c).

 

4.10      Documentation.

 

(a)          During
term of this Agreement, Licensee shall deliver to PLx (in all cases as soon as reasonably practicable) copies
of the following (collectively, “Documentation”):

 

(i)          All
applications, notices, inspection requests or reports, exceptions, determinations, correspondence or other documents provided by
or to, or filed with, any Applicable Regulatory Authority with respect to any Licensed Product;

 

(ii)         Whether
or not included in 4.10(a)(i) above, all Clinical Trial Data with respect to any Licensed Product; and

 

(iii)        all
financial reports, press releases, or other disclosure materials published or disseminated by Licensee that discuss or relate
to this Agreement or any Licensed Product. 

 

    	 	10	 

     

    

 

(b)          Licensee
further agrees that it will provide PLx with

 

(i)          an
English-language translation of all Documentation within four months of such Documentation being submitted; and

 

(ii)         
a Chinese-language translation of all Documentation within one month of such Documentation being submitted.

 

(c)          PLx
is hereby granted an exclusive license to use all Documentation in PLx’s own research and development activities and
regulatory submissions, provided that, during the term of this Agreement, such research and development activities and regulatory
submissions are conducted solely outside of the Licensed Territory.

 

4.11      Optional
Licensed Territory.

 

(a)          PLx
agrees that from the Effective Date through [*], PLx will not grant, other than to Licensee, any license to
develop, register, manufacture, have manufactured, use, distribute, have distributed, Sell, offer to Sell, import,
lease, loan or otherwise Commercialize Licensed Product(s) within the Optional Licensed Territory. 

 

(b)          Any
such license granted to Licensee with respect to the Optional Licensed Territory shall be granted only pursuant to
an amendment to this Agreement, or pursuant to a separate definitive license and commercialization agreement to be entered
into between PLx and Licensee or its respective Affiliates regarding the Commercialization of Licensed
Products.

 

(c)          Licensee
shall, within [*] days of receipt of any invoice from PLx for the external costs of the prosecution, maintenance, or enforcement
of Patent Rights in the Optional Licensed Territory from the Effective Date through [*], deliver to PLx,
via wire transfer of immediately available funds, payment in the amount of such invoiced costs.

 

5.
PAYMENTS AND REPORTS

 

5.1        In
consideration of rights granted by PLx to Licensee under this Agreement, Licensee will pay PLx
as follows:

 

(a)          PLx
and Licensee confirm that a one-time, non-refundable, non-creditable payment in the amount of [*] was paid within 30 days
from the Original Agreement Effective Date.

 

(b)          Licensee
will pay PLx a running royalty equal to [*] of Net Sales of Licensed Products (which running royalty will
be reduced to (i) [*] upon the expiration of the last to expire of the Patent Rights having at least one Valid Claim covering the
Licensed Products, with such reduced royalty payable for a period of [*] years after such expiration; and (ii) [*] after the expiration
of the [*] period under point (i) above).

 

(c)          Licensee
will pay PLx, within [*] of the Effective Date and whether or not any royalties become due in the future, a [*] non-refundable
advance payment of royalties, such payment to be credited against the first [*] of payments due pursuant to Section 5.1(b) or Section
5.1(d).

 

    	 	11	 

     

    

 

(d)          If,
in the calendar year ended December 31, [*] or any subsequent calendar year until the expiration of all Patent Rights having
at least one Valid Claim covering the Licensed Products, the annual running royalty payments required to be made
pursuant to Section 5.1(b) do not aggregate to an amount greater than or equal to [*], then, regardless of whether there are Sales,
an additional annual royalty payment in the amount equal to the difference between [*] and the aggregate running royalty payments
actually made pursuant to Section 5.1(b) for such year, shall be due and payable within [*] days after the end of such calendar
year.

 

(e)          Licensee
will pay PLx an annual administrative fee of [*], initially payable on the first anniversary of the Effective Date,
and then on each anniversary thereof until annual royalties totaling at least [*] are being paid under Section 5.1(b) and/or 5.1(d).

 

(f)          In
the event of a significant change in market conditions (including, without limitations, in the regulatory, distribution and promotional
conditions), PLx agrees, when requested by Licensee, to discuss in good faith a change in royalty terms. For example,
conditions which may initiate such a discussion include (i) a greater than [*] reduction in reimbursement price of the Licensed
Products by a relevant governmental authority, (ii) a new competing product with superior characteristics or (iii) a generic
similar product achieving a market share in excess of [*] in the Licensed Territory.

 

5.2        PLx
is solely responsible for payment of any royalty obligations to System with respect to any of the foregoing. Licensee
shall be responsible for all license fees incurred in connection with or related to, directly or indirectly, the performance of
its duties hereunder.

 

5.3        During
the term of this Agreement and for [*] years thereafter, in addition to the information provided under Section 5.4 below,
Licensee agrees to keep complete and accurate records of its and its Sublicensees’ Sales and Sales
of Licensed Product(s) under the license granted in this Agreement, and any amounts otherwise due hereunder, in sufficient
detail to enable Licensee to calculate and confirm the Royalties and other amounts payable hereunder and to provide
access to and copies of such records on a periodic basis to PLx and its agents at such times and in such manner as PLx
shall reasonably request. Licensee agrees to permit PLx or its representatives, at PLx’s expense, to
periodically examine its books, ledgers, and records during regular business hours for the purpose of and to the extent necessary
to verify any report required under this Agreement. Such audits may, at PLx’s sole discretion, consist of a
self-audit conducted by Licensee and certified in writing by an authorized officer of Licensee. PLx will endeavor
to make sure the audits cause minimal disruption with the business of the Licensee and to limit the frequency of audit to
once per year, unless in the reasonable discretion of PLx more frequent audit is determined to be appropriate. If the amounts
due to PLx are determined to have been underpaid by [*] or greater, for the period being audited, Licensee will pay
the cost of the examination and accrued interest at a rate of [*] above the prime rate, where the prime rate is defined as prime
rate as published in the U.S. edition of the Wall Street Journal on the quarterly due date for which the payment was due.

 

    	 	12	 

     

    

 

5.4        Royalties
accrue as payments or consideration upon which a Royalty is due are actually received by Licensee, and are due and
payable within [*] days after the end of the calendar quarter in which payment is received. Beginning immediately after the Effective
Date, Licensee shall deliver to PLx a true and accurate written report certified by an authorized officer of
Licensee, even if no payments are due PLx, giving the particulars of the business conducted by Licensee and
its Sublicensee(s), if any, during the preceding three (3) calendar months under this Agreement as are pertinent
to calculating payments hereunder. This report will include at least:

 

(a)          The
Net Sales and total quantities of Licensed Product(s) sold; and

 

(b)          The
calculation of Royalties and amounts payable thereon; and

 

(c)          The
total royalties computed and due PLx; and

 

(d)          All
other consideration received by Licensee relating to Licensed Product(s) and

 

(e)          Sublicenses;
and

 

(f)          All
other amounts due PLx herein.

 

5.5

 

(a)          Within
[*] days after the end of each fiscal quarter following the Effective Date (until the first submission of an NDA), Licensee
shall deliver to PLx (in a form reasonably satisfactory to PLx) a written report summarizing Licensee’s
(and any Sublicensee’s) efforts and accomplishments during the preceding fiscal quarter in diligently developing Licensed
Subject Matter in the Licensed Territory and Licensee’s (and Sublicensee’s) development plans
for the upcoming fiscal quarter.

 

(b)          Within
[*] days after the end of each fiscal quarter following the first submission of an NDA, Licensee shall deliver
to PLx (in a form reasonably satisfactory to PLx) a written report summarizing Licensee’s (and any Sublicensee’s)
efforts and accomplishments during the preceding fiscal quarter in diligently commercializing Licensed Subject Matter in
the Licensed Territory and Licensee’s (and Sublicensee’s) commercialization plans for the upcoming
fiscal quarter.

 

5.6        All
amounts payable by Licensee hereunder, or otherwise referred to herein, shall be paid and denominated in United States funds
without deductions for taxes, assessments, fees, or charges of any kind. When Licensee receives Royalties from a
Sublicensee in a currency other than United States dollars, the earned Royalties first will be determined in the
foreign currency in the country in which such royalties were earned, and then converted into equivalent United States funds.
The exchange rate will be that rate published in the U.S. edition of the Wall Street Journal on the last day of the reporting
period, and will be quoted in the continental terms method of quoting exchange rates (local currency per United States dollar).
All Royalty payments which are not paid by Licensee by the sixty-first (61st) day after each quarterly
payment date shall bear interest at a rate of three percent above the Prime Rate of United States Federal Reserve Bank, New York,
New York. Such interest payments shall be calculated from the quarterly due dates until the payment is received by PLx.
Payments shall be made via electronic funds transfer to:

 

    	 	13	 

     

    

 

Correspondent Bank: 

[*]

Credit to Beneficiary:

[*]

For Further Credit:

[*] 

 

Licensee shall
be responsible for any wire transfer fees and promptly notify PLx of such transfer.

 

6.
TERM AND TERMINATION

 

6.1        The
term of this Agreement is from the Effective Date for as long as Licensed Products are sold in the Licensed
Territory, unless earlier terminated pursuant to Section 6.2 or 6.3 below.

 

6.2        If
Licensee is current with its payments under Section 5, then at any time after the Effective Date, Licensee may
terminate this Agreement upon [*] written notice to PLx.

 

6.3        Subject
to any rights that survive termination, this Agreement will earlier terminate in its entirety:

 

(a)          upon
[*] days written notice from: (i) PLx if Licensee becomes bankrupt or insolvent and/or if the business of Licensee
is placed in the hands of a receiver, assignee, or trustee, whether by voluntary act of Licensee or otherwise, or if Licensee
seeks similar protection or relief under any equivalent mechanism provided for by the regulations of any applicable jurisdiction;
or (ii) Licensee if PLX becomes bankrupt or insolvent and/or if the business of PLx is placed in the hands
of a receiver, assignee, or trustee, whether by voluntary act of PLx or otherwise, or if PLx seeks similar protection
or relief under any equivalent mechanism provided for by the regulations of any applicable jurisdiction; or

 

(b)          upon
[*] days written notice from PLx if Licensee breaches or defaults on its obligation to make payments (if any are
due) or reports, in accordance with the terms of Section 5 hereunder, unless, before the end of the day period, Licensee
has cured the default or breach and so notifies PLx, stating the manner of the cure; or

 

(c)          upon
[*] days written notice from PLx if Licensee is deemed to be non-compliant with any regulation imposed by any Applicable
Regulatory Authority, as determined by PLx pursuant to Section 4.9 hereunder, unless, before the end of the day period,
Licensee has cured the non-compliance and so notifies PLx, stating the manner of the cure; or

 

    	 	14	 

     

    

 

(d)          upon
[*] days written notice from PLx if Licensee breaches or defaults on any other material obligation under this Agreement,
unless, before the end of the day period, Licensee has cured the default or breach and so notifies PLx, stating the
manner of the cure; or

 

(e)          upon
[*] days written notice from Licensee if PLx breaches or defaults on any material obligation under this Agreement,
unless, before the end of the day period, PLx has cured the default or breach and so notifies Licensee, stating the
manner of the cure; or

 

(f)          upon
[*] days written notice from PLx if Licensee fails to reimburse PLx for payment of PLx’s invoices
to prosecute, maintain and enforce Patent Rights as required by Section 7.2; or

 

(g)          at
the sole option of PLx, upon any Change in Control of Licensee, unless the party or parties succeeding to
such control execute and deliver to PLx [*] days of such Change in Control—in a form approved by PLx,
which approval will not be unreasonably withheld or delayed—an agreement affirming such party’s or parties’ acceptance
of the terms of this Agreement and, if applicable (in the case of a sale of assets, merger, or other transaction in which
Licensee is not the surviving entity), assumption of Licensee’s obligations hereunder; or

 

(h)          at
the sole option of PLx, upon a failure of Licensee to meet any Milestone set forth under Section 4.4, subject
to the right of Licensee to submit a Revised Milestone Plan as set forth therein; or

 

(i)          at
any time by mutual written agreement between Licensee and PLx, upon [*] days written notice to all parties and subject
to any terms herein which survive termination.

 

6.4        If
this Agreement is terminated before the expiration of the Patent Rights having at least one Valid Claim covering
the Licensed Products sold in the People’s Republic of China the following shall apply:

 

(a)          nothing
herein will be construed to release either party of any obligation matured prior to the effective date of the termination; and

 

(b)          in
case of termination by Licensee in accordance with Section 6.2 and by PLx in accordance with Section 6.3 (a), (b),
(c), (d), (f), (g) and (h), then (i) after the effective date of the termination, and for a period of no longer than [*], Licensee
may Sell all Licensed Product(s) and parts thereof it has on hand as of the date of termination, if Licensee
pays earned Royalties thereon and any other amounts according to the terms of Section 5; and (ii) Licensee covenants
and agrees to continue to be bound by the provisions of Sections 10 (Indemnification), 11 (Use of Name), and 12 (Confidential Information
and Publication) of this Agreement; and (iii) Licensee shall return all information, documents, notes and the like,
together with all media upon which it or they are stored or represented, relating to the Licensed Subject Matter which is
confidential or proprietary, in the reasonable opinion of PLx, including any Confidential Information, and shall
further permanently delete all such information, documents, notes and the like from machine memories or other storage devices or
media. In lieu of returning any machine memory or other data that contains a copy of information otherwise delivered to PLx
in a convenient format, Licensee may delete from such memory all of the information delivered to PLx in a convenient
format and certify such deletion to PLx; and (iv) PLx shall be deemed to have received from Licensee an assignment
of all of Licensee’s right, title and interest in and to use of the Inventions, and Licensee shall have
no continuing rights with respect thereto, to the extent that such use is in connection with or a part of the manufacture, sale,
use or distribution of any Licensed Product.

 

    	 	15	 

     

    

 

7.
INFRINGEMENT

 

7.1        If
Licensee is informed or becomes aware of any patent held by a third party that Licensee reasonably believes would
be infringed by the continued Sale of Licensed Product(s), or by the use of Licensed Product(s) by its customers,
or of the possible infringement by a third party of the Patent Rights granted hereunder, Licensee agrees to promptly
inform PLx of same in writing. 

 

7.2        PLx
shall be responsible for prosecuting, maintaining and enforcing Patent Rights. Licensee shall, within [*] days of receipt
of invoices from PLx for the costs of the prosecution, maintenance or enforcement of Patent Rights in the Licensed Territory,
deliver to PLx, via wire transfer of immediately available funds, payment in the amount of such invoiced costs.

 

7.3        In
any infringement suit or dispute, the parties agree to cooperate fully with each other. At the request and expense of the party
bringing suit, the other party will permit access to all relevant personnel, records, papers, information, samples, specimens,
etc., during regular business hours.

 

7.4        PLx
may request that Licensee join the prosecution of an infringer. If Licensee agrees, then Licensee and PLx
shall jointly enforce Patent Rights against infringement by third parties and shall be entitled to retain any recovery from
such enforcement. After deducting Licensee’s and PLx’s third-party, documented, unrecovered reasonable
legal expenses incurred exclusively from such suit, any remaining recovery shall be divided equally between Licensee and
PLx, and PLx will be entitled to a royalty payment on Licensee’s portion of such recovery. Such actions
specified in this Section 7.4 shall be subject to the Patent License Agreement.

 

8.
ASSIGNMENT; CHANGE IN CONTROL

 

8.1        This
Agreement may not be assigned by Licensee without the prior written consent of PLx, except that Licensee
may assign its rights hereunder to an Affiliate of Licensee without such prior written consent.

 

8.2        No
later than [*] days after the effectiveness of any Change in Control of Licensee, Licensee shall give written
notice to PLx of such Change in Control, upon receipt of which PLx shall have the option to terminate this
Agreement pursuant to, and subject to the provisions of, Section 6.3(g).

 

    	 	16	 

     

    

 

9.
PATENT MARKING AND MAINTENANCE

 

Licensee shall permanently and legibly
mark all products and documentation manufactured or Sold by its Affiliates or Sublicensee(s) pursuant to this
Agreement with a patent notice as may be permitted or required under Title 35, United States Code, or if such marking is
not practicable, shall so mark the accompanying outer box or product insert for Licensed Product(s) accordingly. Additionally,
Licensee agrees to use the PLxGuardTM mark on all Products, unless otherwise requested by
PLx and provided such use is allowed by the Applicable Regulatory Authority.

 

10.
INDEMNIFICATION

 

10.1      Licensee
agrees to hold harmless and indemnify, on a current basis, PLx, its parent and subsidiary entities, System, and
each of their respective Boards of Directors, officers, employees, affiliates and agents from and against any liabilities, fines,
penalties, damages, claims, demands, causes of action, or costs of suit, including reasonable attorney’s fees and costs,
arising from or relating to any action or inaction by Licensee, Licensee's use of any Licensed Product or
exercise of its rights hereunder or Licensee's business or operations, including without limitation costs arising on account
of any injury or death of persons or damage to property, costs associated with any government investigation whether or not arising
in whole or in part from the actual or alleged misconduct or negligence, including gross negligence, of any party indemnified hereunder.
Each person indemnified pursuant to the foregoing shall be a third-party beneficiary of this section. PLx agrees to hold
harmless and indemnify Licensee, its Board of Directors, officers, employees, and agents from and against any claims, demands,
or causes of action whatsoever, or costs of suit or reasonable attorney’s fees, arising out of or resulting from a material
breach of PLx’s obligations to the System with respect to the Patent Rights, including PLx’s
obligations to make payments to the System.

 

10.2      Insurance

 

(a)          Licensee
shall secure and keep in full force and effect product liability insurance providing coverage for the Licensee, as its interest
may appear, in an amount [*] that is customary for the Licensed Territory, when and if available in the Licensed Territory.

 

(b)          Licensee
shall provide PLx with written evidence of such insurance when in force and on the anniversary thereof for each following
year during the term of this Agreement. Licensee shall provide PLx with written notice at least [*] days prior
to the cancellation, non-renewal or material change in such insurance when in place.

 

11.
USE OF NAME

PLx may not use the name of Licensee—and
Licensee may not use the name of either PLx or System—without express written consent, except to the
extent required by law, or in connection with enforcing its rights under this Agreement or with respect to the Licensed
Property; except that the Parties agree to disclosure of the existence of this Agreement on their respective
websites and in any joint or separate press release.

 

12.
CONFIDENTIAL INFORMATION AND PUBLICATION

 

12.1      The
Parties hereby incorporate by reference their obligations under that certain Confidentiality Agreement dated November 15,
2010 (the “Confidentiality Agreement”), and agree that such obligations shall (a) extend to any confidential
information provided by either party pursuant to this Agreement and (b) survive until the third anniversary of the termination
of this Agreement or the survival period contemplated in the Confidentiality Agreement, whichever is longer.

 

    	 	17	 

     

    

 

12.2      Licensee
shall not publish or make available for publication any research related to Licensed Subject Matter without the prior written
consent of PLx, which consent shall not be unreasonably withheld or delayed.

 

13.
PATENTS AND INVENTIONS

 

13.1      Except
as otherwise provided by written agreement of the Parties with respect to certain products or applications for which PLx,
in its sole and absolute discretion, deems it beneficial to establish alternative arrangements, the Parties agree that the Licensed
Property includes all derivative works, copyrights, inventions, discoveries and other intangible personal property or rights
created by Licensee or its agents in connection with the transactions and activities contemplated herein (collectively,
the “Inventions”), and that all such Inventions shall be owned (subject to the Patent License Agreement)
solely by PLx and shall be “works made for hire” for the benefit of PLx. At its option, PLx will
prepare and file the appropriate patent applications as to the Licensed Territory, and Licensee will reimburse the
reasonable cost of searching, preparing, filing, prosecuting, defending, and maintaining same with regard to the Licensed Territory.
Licensee shall cause to be executed and shall deliver to PLx copies of all instruments, certificates and agreements
as PLx shall reasonably request to establish and defend PLx’s rights in Inventions. To the extent that
Licensee shall obtain any rights to the intellectual property rights of others in connection with its performance hereunder,
or that relate to any use of the Licensed Subject Matter, Licensee shall obtain for PLx rights equal to those
of Licensee, except that such rights shall survive termination of this Agreement. Licensee shall keep PLx
fully informed of any additions to the Licensed Property resulting from its activities contemplated or permitted hereunder,
including any Inventions or licenses created or obtained. Among other purposes, the foregoing is intended to provide PLx
with such rights as Licensee held with respect to the Inventions, or any use thereof, upon the termination of this
Agreement, except that PLx’s rights to utilize any rights obtained from third parties that relate to the Licensed
Property shall continue for not less than [*] years following any termination of this Agreement. PLx shall have
the right to audit Licensee’s and its agents and contract counterparties’ operations relating to the Licensed
Property at any time, and to interview all persons and take copies of all writings, data and information, howsoever stored,
recorded or maintained, as it shall reasonably deem appropriate under the circumstances, and Licensee shall ensure that
any agreements with agents or others relating to the Licensed Property, other than licenses to commercial party end users
who have no right or obligation to create any portion of the Licensed Property, ensure that PLx maintains such rights.
Licensee shall cause its agents and employees to execute and deliver such instruments, agreements and certificates as shall
be reasonably necessary to accomplishment of the foregoing and the perfection of PLx’s rights in the Licensed Property,
including any rights to use, relicense or sale thereof.

 

    	 	18	 

     

    

 

13.2      If
Licensee develops a new Invention that may enhance the Licensed Property, Licensee will promptly notify
PLx and provide PLx with adequate information necessary to evaluate such Invention. PLx agrees to consider
new Inventions and to in good faith negotiate with Licensee to arrive at mutually agreeable consideration for new
Inventions. Licensee shall be entitled to use such new Inventions, to the extent they may be applicable
to other products not included under this Agreement, for its own exclusive use within the Licensed Territory at no
cost to Licensee (provided that such new Inventions are not used in association with a Competing Product and
that PLx is entitled to use such new Inventions at no cost to PLx in jurisdictions outside the Licensed
Territory) subject to the conditions of Section 6.4(b)(iv).

 

14.
GOVERNING LAW; JURISDICTION; VENUE

 

14.1       This
Agreement shall be governed in all respects, including valid interpretation and effect, by the laws of the Special Administrative
Region of Hong Kong, the People’s Republic of China. The courts of Special Administrative Region of Hong Kong, the People’s
Republic of China, shall have exclusive jurisdiction and venue over any dispute arising out of this Agreement, and the Parties
hereby consent to the jurisdiction of such courts.

 

15.
GENERAL

 

15.1      This
Agreement constitutes the entire and only agreement between the parties with respect to PLx’s license to Licensee
of the Licensed Subject Matter for use in the Licensed Field and all other prior negotiations, representations, agreements,
and understandings are superseded hereby. No agreements altering or supplementing the terms hereof may be made except by a written
document signed by both parties.

 

15.2      All
correspondence and notices required by this Agreement shall be delivered by internationally recognized common carrier, addressed
to:

 

PLx Pharma LLC

8285 El Rio, Suite 130

Houston, Texas 77007

FAX: 713.842.3052

PHONE: 713.842.1249

 

or in the case of Licensee
to:

 

Lee’s
Pharmaceutical Holdings Limited

Unit 110-111, Bio-Informatics
Centre

No.2 Science Park West Avenue

Hong Kong Science Park, Shatin

Hong Kong

FAX: 852-2314-1708

PHONE: 852-2314-1282

 

or other addresses as may be given from
time to time under the terms of this notice provision.

 

15.3      PLx
and Licensee shall comply with all applicable federal, state and local laws and regulations in connection with their
respective activities pursuant to this Agreement, including the transfer of products and technical data.

 

    	 	19	 

     

    

 

15.4      It
is understood that certain technologies and products are subject to United States laws and regulations controlling the export
of technical data, computer software, laboratory prototypes and other items (including but not limited to the Arms Export Control
Act, as amended, the Export Administration Regulations and U.S. economic sanctions), and their obligations hereunder are contingent
on compliance with applicable United States export laws and regulations. The transfer of certain technical data and items may
require a license or authorization from the appropriate agency of the United States Government and/or written assurances by Licensee
that Licensee shall not export data or commodities to certain foreign countries without prior approval of such agency
(including as controlled under U.S. law, release of technology, source code and technology data to non-U.S. persons). PLx
neither represents that a license shall not be required nor that, if required, it shall be issued.

 

15.5      Failure
of PLx to enforce a right under this Agreement will not act as a waiver of that right or the ability to later assert
that right relative to the particular situation involved.

 

15.6     The
failure or delay of a party to enforce or to exercise, at any time for any period of time, any provision hereof or any right or
remedy hereunder shall not be construed as a waiver of such provision or right or remedy or of the right of such party to enforce
or exercise the same, provided, however, that such right or remedy is not time-barred or otherwise precluded by law or by a writing
expressly waiving such right or remedy and signed by that party by the party seeking to assert such right or remedy. The written
waiver by either party of a breach of any term or provision of this Agreement by the other party shall not be construed as a waiver
of any subsequent breach. 

 

15.7      Except
as expressly and specifically provided under this Agreement, the parties agree that neither party is granted any implied
rights to or under any of the other party’s current or future patents, trade secrets, copyrights, moral rights, trade or
service marks, trade dress, or any other intellectual property rights. 

 

15.8      Licensee
and PLx agree their relationship with each other, as established by this Agreement, is that of licensor and
licensee, and that this Agreement does not, is not intended to, and shall not be construed to establish a partnership or
joint venture, nor shall this Agreement create or establish an employment, agency or any other relationship. Licensee
shall not have any right, power or authority to, nor shall it represent itself as having any authority to, assume, create
or incur any expense, liability or obligation, express or implied, on behalf of PLx, or otherwise act as an agent for such
parties for any purpose. 

 

15.9      Headings
are included herein for convenience only and shall not be used to construe this Agreement.

 

15.10     If
any part of this Agreement is for any reason found to be unenforceable, all other parts nevertheless remain enforceable.

 

    	 	20	 

     

    

 

IN WITNESS WHEREOF, the Parties
hereto have caused this to be executed by their duly authorized representatives.

 

	PLx:	 
	 	 
	PLx Pharma LLC	 
	 	 
	By:	/s/ Ronald R. Zimmerman	 
	Ronald R. Zimmerman, President and CEO	 
	Date: June 19, 2015	 
	 	 
	LICENSEE:	 
	 	 
	LEE’S PHARMACEUTICAL holdings LIMITED	 
	 	 
	By:	/s/  Dr. Li Xiaoyi	 
	Dr. Li Xiaoyi, Chief Executive Officer	 
	Date:  June 19, 2015	 
	 	 
	Seal	 
	 	 
	Zhaoke Pharmaceutical (HEFEI) Co. Ltd.	 
	 	 
	By:	/s/  Dr. Li Xiaoyi	 
	Dr. Li Xiaoyi, Chief Executive Officer	 
	Date: June 19, 2015	 
	 	 
	Seal	 
	 	 
	LEE’S PHARMACEUTICAL (GUANGZHOU) LIMITED	 
	By:  	/s/  Dr. Li Xiaoyi	 
	Dr. Li Xiaoyi, Chief Executive Officer	 
	 	 
	Date:   June 19, 2015	 
	 	 
	Seal	 

 

    	 	21

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00250-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00250-of-00352.parquet"}]]